GlassScriptPhysician profile
John S Burr
NPI 1770535940
$11,710.12
in general payments reported to CMS, 2019-2025
36 companies · $8,420 in 2025
The $8,420 reported for 2025 was more than what 92% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.90 · 2020: $115 · 2021: $404 · 2022: $747 · 2023: $788 · 2024: $1,146 · 2025: $8,420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $5,555 · Food and Beverage: $3,853 · Travel and Lodging: $946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $5,554.99 |
| Food and Beverage | $3,852.67 |
| Travel and Lodging | $946.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,662.95 | 2025 | |
| Jazz Pharmaceuticals INC. | $1,190.83 | 2020-2025 | Xywav |
| Inspire Medical Systems, INC. | $554.79 | 2023-2025 | Inspire |
| Glaxosmithkline, LLC. | $467.72 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $467.00 | 2022-2025 | Ofev, Jascayd |
| Astrazeneca Pharmaceuticals LP | $423.76 | 2021-2025 | Fasenra, Airsupra, Breztri |
| Vapotherm INC | $149.37 | 2020-2022 | |
| Insmed, INC. | $142.90 | 2024-2025 | Arikayce, Brinsupri |
| Axsome Therapeutics, INC. | $138.04 | 2023-2025 | Sunosi |
| Pinnacle Biologics, INC | $135.66 | 2024 | Photofrin |
| United Therapeutics Corporation | $122.79 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $120.37 | 2023-2025 | Lumryz |
| Amgen INC. | $115.03 | 2022-2025 | Tezspire |
| Viatris Specialty LLC | $105.96 | 2025 | Yupelri |
| Harmony Biosciences LLC | $92.10 | 2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $90.90 | 2019 | |
| Genzyme Corporation | $78.91 | 2023-2025 | |
| Verona Pharma, INC. | $73.60 | 2025 | Ohtuvayre |
| Itamar Medical INC | $72.04 | 2023 | Watchpatone |
| Boston Scientific Corporation | $59.07 | 2022 | |
| Edwards Lifesciences Corporation | $57.63 | 2023 | Hemosphere |
| Takeda Pharmaceuticals U.S.A., INC. | $50.87 | 2024-2025 | Glassia, Hyqvia |
| Regeneron Healthcare Solutions, INC. | $46.92 | 2021-2024 | Dupixent |
| Grifols USA, LLC | $43.27 | 2025 | Prolastin-C Liquid |
| Electromed, INC. | $37.69 | 2023-2024 | Smartvest |
| Mylan Specialty L.P. | $37.42 | 2022-2023 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $35.27 | 2022-2024 | |
| Lilly USA, LLC | $27.23 | 2025 | Zepbound |
| Breas Medical, INC. | $23.24 | 2025 | Vivo 45 Ls, Vivo 1/2 |
| Resmed Corp | $20.46 | 2025 | |
| Fisher & Paykel Healthcare INC | $18.18 | 2024 | Fisher & Paykel Healthcare |
| Merck Sharp & Dohme LLC | $15.68 | 2021 | |
| Arbor Pharmaceuticals, INC. | $15.34 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.39 | 2021 | |
| Ambu INC. | $4.74 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Burr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.